Molecular Profiles said the company is to adopt Juniper Pharma Services as its new brand name.

The move has coincided with its Boston-based parent company Columbia Laboratories, Inc. adopting its new brand identity as Juniper Pharmaceuticals, Inc.

A new corporate website, reflecting the Juniper brand identity, has been launched at www.juniperpharma.com.

“The single Juniper brand formalizes the experience and capabilities that has been built in Boston and Nottingham,” said Nikin Patel, president at Juniper Pharma Services. “The name change also coincides with the expansion of our service offering to the North American market.

“As we move forward under the Juniper brand, we remain committed to addressing the needs and challenges of the companies that rely on our contract pharmaceutical development and manufacturing services.”

The contract development and manufacturing organization (CDMO) specializes in advanced characterization, IP consulting, formulation development, analytical services and clinical manufacturing.

The science-led manufacturer has well established tableting and capsule filling capabilities focused on delivering product supply for small scale early trials up to Phase III and the rebranding initiative coincides with increased demand for topical and oral dosage form products.

Its new logo includes an icon featuring two interlocked rings, which symbolize the synergies between Juniper’s proprietary women’s health R&D program and contract pharmaceutical development expertise at Juniper Pharma Services.